Mega Genomics Limited reported no changes to its share capital structure for the month ended 31 March 2026, according to its latest monthly return filed with Hong Kong Exchanges and Clearing Limited on 2 April 2026.

• Authorised capital remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to USD 50,000.

• Issued share capital was unchanged at 224.30 million ordinary shares. The company held no treasury shares, leaving total issued shares at the same level as the previous month.

• The issuer confirmed compliance with the Main Board’s minimum public-float requirement, which mandates at least 25% of issued shares be held by the public.

• No share options, warrants, convertible securities or other share-issuing arrangements were outstanding or initiated during the month, and there were no Hong Kong Depositary Receipts.

Director Jiang Jing signed the regulatory filing, affirming that all applicable listing rules and legal requirements were met. With its capital base steady and no fresh equity instruments introduced, Mega Genomics enters the second quarter of 2026 with an unchanged share structure and sufficient market float.